Xingkerong Pharmaceutical (06833) issued an announcement. The Group expects the year ended December 31, 2023 (this year...
According to Zhitong Finance App, Xing Kerong Pharmaceutical (06833) announced that the net profit attributable to corporate equity holders for the year ended December 31, 2023 (this year) is about RMB 42 million, a decrease of about RMB 27.5 million or about 39.6% compared with the net profit attributable to the company's equity holders of RMB 69.5 million for the year ended December 31, 2022.
According to the announcement, the decrease in net profit was mainly due to the increase in administrative expenses due to the Group's expansion of the medical and aesthetic drug research and manufacturing division and the business operations of the medical and aesthetic division this year.